SCHEMBL560354

SCHEMBL560354

O=C(O)c1cc(Cl)cc(Br)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 2/20 0.70
HCAR1 Q9BXC0 1/20 0.59
HCAR2 Q8TDS4 2/20 0.47
POLB P06746 2/20 0.47
TTR P02766 2/20 0.46
RXRA P19793 2/20 0.45
RXRB P28702 2/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.44
WDR5 P61964 1/20 0.44
ACLY P53396 1/20 0.44
GPR139 Q6DWJ6 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41
SRD5A2 P31213 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29912726 1.00 TPMT (0.70) TPMTHCAR1HCAR2POLBTTR
SCHEMBL8361 0.83 TTR (0.56) TPMTHCAR1HCAR2POLBTTR
SCHEMBL28214359 0.83 TPMT (1.00) TPMTHCAR1HCAR2TTRRXRA
SCHEMBL475757 0.83 TTR (0.56) TPMTHCAR1HCAR2POLBTTR
SCHEMBL69625 0.83 TPMT (0.89) TPMTHCAR1HCAR2TTRRXRA
SCHEMBL23501889 0.83 TTR (0.56) TPMTHCAR1HCAR2POLBTTR
SCHEMBL23699 0.83 TPMT (1.00) TPMTHCAR1HCAR2TTRRXRA
SCHEMBL30973118 0.83 TPMT (0.46) TPMTHCAR1HCAR2POLBRXRA
SCHEMBL27294868 0.83 TPMT (0.46) TPMTHCAR1HCAR2POLBRXRA
SCHEMBL986020 0.82 TPMT (0.44) TPMTHCAR1HCAR2POLBRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117263908-A Preparation of 1-pyridylpyrazole amide compound and intermediate thereof 湖南化工研究院有限公司 2023-12-22 CN claimed
CN-1257484-A Synthesis of intermediates useful in preparing tricyclic compounds SCHERING CORP (US) 2000-06-21 CN claimed
WO-2024227436-A1 COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2024-11-07 WO disclosed
WO-2024178004-A2 THERAPEUTIC COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-08-29 WO disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 US disclosed
CN-118239916-A Polysubstituted benzo dibenzo five-membered ring compound and application thereof 烟台显华科技集团股份有限公司 2024-06-25 CN disclosed
CN-118108574-A Fluorine-containing compound with trimesic structure and application thereof 烟台显华科技集团股份有限公司 2024-05-31 CN disclosed
CN-111527082-B Organic electronic device comprising an organic semiconductor layer 诺瓦尔德股份有限公司 2023-07-04 CN disclosed
EP-3867237-B1 PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2023-06-07 EP disclosed
CN-111032034-B Spiro compounds and methods of making and using the same H.隆德贝克有限公司 2023-05-02 CN disclosed
US-11462691-B2 Organic electronic device comprising an organic semiconductor layer NOVALED GMBH (DE) 2022-10-04 US disclosed
WO-2007146838-A2 SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS ICOS CORPORATION (US) 2007-12-21 WO disclosed
US-20070099885-A1 Antibacterial macrocycles with substituted biphenyl AICURIS GMBH & CO. KG (DE) 2007-05-03 US disclosed
EP-1697400-A1 BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES AiCuris GmbH & Co. KG (DE) 2006-09-06 EP disclosed
WO-2005058943-A1 BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES AICURIS GMBH & CO. KG (DE) 2005-06-30 WO disclosed
CN-1178919-C Synthesis of intermediates useful in preparing tricyclic compounds ���鹫˾ 2004-12-08 CN disclosed
CN-1257484-A Synthesis of intermediates useful in preparing tricyclic compounds SCHERING CORP (US) 2000-06-21 CN disclosed
US-5866610-A Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical as inhibitors of the cellular NA+/H+ exchange or as a diagnostic, and pharmaceutical containing them HOECHST AKTIENGESELLSCHAFT (DE) 1999-02-02 US disclosed
EP-0612723-B1 Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them HOECHST AG (DE) 1997-08-27 EP disclosed
EP-0612723-A1 Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099885-A1 Antibacterial macrocycles with substituted biphenyl NOD2, AHR, BCL2 TPMT 297/4885HCAR1 1376/4885HCAR2 1651/4885
US-20240226115-A1 AXL INHIBITOR COMPOUNDS AXL, BTK, MERTK TPMT 1228/4885HCAR1 2532/4885HCAR2 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.